A new Houston program is assisting startups creating new therapies and technologies in the field of regenerative medicine.
HOUSTON (September 27, 2019) By Andrea Leinfelder of The Houston Chronicle – Houston Healthspan Innovation Group, which publicly announced its program last week, launched in July to provide startups with 10,000 square feet of lab space and technologies and access to a team with expertise in biology, clinical diseases, therapeutic delivery systems, finance and marketing.
Houston Healthspan Innovation Group, which publicly announced its program last week, launched in July to provide startups with 10,000 square feet of lab space and technologies and access to a team with expertise in biology, clinical diseases, therapeutic delivery systems, finance and marketing.
Two of the initial client companies are Rejenevie Therapeutics, a developer of therapies for immune system restoration and age-related diseases, and Tissue Genesis, a creator of stem cell isolation technologies. The companies have relocated from New Jersey and Hawaii, respectively, to advance their research and development, according to a news release.
“With two collaborator companies like Rejenevie and Tissue Genesis working out of our Houston Healthspan Bio Labs, we can offer significant resources and expertise for start-up and joint-venture partners to thrive and succeed,” Eric Schaeffer, chief strategy officer for Houston Healthspan, said in the news release.
Houston Healthspan Innovation Group, with lab space located at 9350 Kirby Drive, suite 300, and corporate offices at 3 Greenway Plaza, suite 1000, was created by Ed Bosarge, who has spent his career applying advanced mathematics to the fields of finance, medicine and energy.
He founded Black Beret Life Sciences in 2014 to search for treatments based on regenerative medicine for cancer, diabetes, neurodegeneration, osteoarthritis and other conditions related to aging. He was also involved in an effort to streamline U.S. Food and Drug Administration approval of safe and effective cellular therapies in the U.S.